Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.53 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.53 |
| ▸ | ELANE | P08246 | 7/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13598526 | 0.81 | NOD2 (0.57) | NOD2NOD1ELANEPLA2G2AKMT2A | |
| SCHEMBL13598532 | 0.79 | NOD2 (0.45) | NOD2NOD1ELANEPLA2G2AKMT2A | |
| SCHEMBL4421828 | 0.78 | NOD2 (0.65) | NOD2NOD1ELANEPLA2G2AKMT2A | |
| SCHEMBL1999770 | 0.76 | ELANE (0.50) | ELANEKMT2AHPGDLMNACYP1A2 | |
| SCHEMBL13598517 | 0.73 | NOD2 (0.40) | NOD2NOD1ELANEPLA2G2AKMT2A | |
| SCHEMBL4421628 | 0.72 | NOD2 (0.60) | NOD2NOD1ELANEKMT2ALMNA | |
| SCHEMBL13598533 | 0.70 | NOD2 (0.43) | NOD2NOD1ELANEPLA2G2AKMT2A | |
| SCHEMBL4252587 | 0.68 | ELANE (0.56) | NOD2NOD1ELANELMNASIRT3 | |
| SCHEMBL4424946 | 0.67 | RAB9A (0.50) | KMT2ALMNATSHRMEN1THRB | |
| Hydrochloric Acid SCHEMBL13684574 | 0.66 | MAPT (0.52) | KMT2AHPGDLMNACYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7626026-B2 | Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment | UNIVERSITY OF BRADFORD (GB) | 2009-12-01 | — | — | US | disclosed |
| EP-1409480-B1 | PYRROLO-INDOLE AND PYRROLO-QUINOLINE DERIVATIVES AS PRODRUGS FOR TUMOUR TREATMENT | UNIV LONDON PHARMACY (GB) | 2007-11-14 | — | — | EP | disclosed |
| US-20040157873-A1 | Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment | INCANTHERA LIMITED (GB) | 2004-08-12 | — | — | US | disclosed |
| EP-1409480-A1 | PYRROLO-INDOLE AND PYRROLO-QUINOLINE DERIVATIVES AS PRODRUGS FOR TUMOUR TREATMENT | THE SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2004-04-21 | — | — | EP | disclosed |
| WO-2002068412-A1 | PYRROLO-INDOLE AND PYRROLO-QUINOLINE DERIVATIVES AS PRODRUGS FOR TUMOUR TREATMENT | SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157873-A1 | Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment | CYP1B1, TOP1, CYP1A1 | NOD2 1847/4885NOD1 718/4885ELANE 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.